BY CHRISTIAN BUNDGAARD
-
Ambu in fulll swing preparing compliance for new sustainability directive
The Danish medtech firm industrious making adjustments to follow a brand-new EU instruction. The general public initial be privy to the outcomes when the yearly record is out in No…
-
Coloplast abused its dominant position in Denmark, rules authority
Danish competition authority finds that Coloplast has used its dominant position to squeeze rivals out of the part of the market supplying municipalities with ostomy aids.
-
Important new EU legislation makes sustainability reporting a task for CFOs
Capitalists and various other stakeholders will certainly quickly have the ability to get better understanding right into firms’ sustainability initiatives, beginning in Febr…
-
Eisai and Biogen secure FDA approval for monthly Alzheimer’s treatment
Both firms are presently going through an evaluation of the application for an once a week subcutaneous variation of Leqembi in the United States.
-
Leo Pharma could be overrun by competitors in market for eczema drugs
Eli Lilly and Galderma remain in a more powerful setting in the fight for dermatitis clients, experts claim. There is space for every person out there, claims Leo Pharma.
-
Analyst: “Novo Nordisk has a credibility problem”
Eli Lilly has the benefit currently, claims the Barclays expert.
-
Three pharmaceutical companies show up for price negotiations
A Teva agent informs media Endpoints that Teva is positive in its capability to browse the effects of individual retirement account.
-
Analyst: “Novo Nordisk has a credibility problem”
Eli Lilly has the advantage now, says the Barclays analyst.
-
FDA approves J&J’s nasal spray for depression
MDD is just one of one of the most typical psychological problems, according to Johnson & Johnson.
-
China discriminates against European medtech companies – EU responds
Chinese medtech business obtain unreasonable benefit in their residential market.
